Regeneron Reports First Quarter 2019 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall St futures slip as US-Iran tensions cloud Middle East peace prospects
- Oil falls as markets await outcome of Iran-US talks, US stocks data
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar firm at 1-year highs as Euro Inflation cools; yen in Intervention zone
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
Regeneron (REGN) Misses Q1 EPS by 101c, Revenues Miss; Provides FY19 Operating Outlook
May 7, 2019 6:36 AM EDTRegeneron (NASDAQ: REGN) reported Q1 EPS of $4.45, $1.01 worse than the analyst estimate of $5.46. Revenue for the quarter came in at $1.712 billion versus the consensus estimate of $1.76 billion.
First quarter 2019 GAAP diluted EPS was $3.99 and non-GAAP diluted EPS was $4.45First quarter 2019 revenues increased 13% to $1.71 billion versus first quarter 2018First quarter 2019 EYLEA® (aflibercept) Injection U.S. net sales increased 9% to $1.07 billion versus first quarter 2018First quarter 2019 EYLEA net sales outside the United States, which are recorded by the Company\'s collaborator Bayer(1), increased 7% to $669 million versus... More